Key Findings
On July 9, 2026, Century Therapeutics announced that promising preclinical data for CNTY-813, its induced pluripotent stem cell (iPSC)-derived islet replacement therapy for Type 1 Diabetes (T1D), will be presented orally at EASD 2026 (European Association for the Study of Diabetes) and the Breakthrough T1D® Clinical & Research Congress 2026. This achievement is built upon the company’s proprietary Allo-Evasion™ 5.0 immune-evading technology, aiming for durable cell engraftment without the need for chronic systemic immunosuppression.
Technical / Clinical Details
CNTY-813 consists of islet cells differentiated from genetically engineered iPSCs, specifically targeting a functional cure for T1D. Traditional islet transplantation requires lifelong, potent immunosuppressants to prevent immune rejection, exposing patients to risks of infection and other serious complications. Century Therapeutics’ Allo-Evasion™ 5.0 technology is designed to eliminate the need for these immunosuppressive drugs. This platform engineers iPSCs with multiple genetic modifications to evade both innate and adaptive immune system attacks. Preclinical studies have confirmed that CNTY-813 functions stably and continues to produce insulin even in immunologically challenged environments, providing data suggestive of long-term normalization of blood glucose levels in diabetes models. Safety profiles and manufacturing processes have been established in preparation for an IND submission.
Background & Context
Type 1 Diabetes is a chronic autoimmune disease where the body’s immune system destroys insulin-producing beta cells in the pancreas, necessitating lifelong insulin injections for glucose management. However, insulin injections alone often fall short of achieving perfect glycemic control, leaving patients at high risk for long-term complications. iPSC-derived islet cell transplantation offers a highly promising approach to address the root cause of the disease by replenishing lost insulin-producing cells. The integration of immune-evasion technology is particularly critical, as it enables the realization of off-the-shelf (allogeneic) cell therapies, which can be produced at scale and delivered to a broader patient population, promising significant health economic impacts.
Strategic Significance & Outlook
Century Therapeutics aims to file an IND for CNTY-813 in Q4 2026, which would pave the way for human clinical trials. This announcement of preclinical data and the IND target represents a groundbreaking advance in T1D treatment, moving a step closer to the ultimate goal of a functional cure without immunosuppression. Clinical success for CNTY-813 is expected to fundamentally improve the lives of T1D patients and have a profound impact on the broader regenerative medicine field. The Allo-Evasion™ 5.0 platform also has potential applications beyond CNTY-813, for other allogeneic cell therapy products.
Source: #
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments